News & Updates

The experimental drug ecopipam helps minimize motor and phonic tics in children and adolescents with Tourette syndrome, in addition to being safe and well tolerated, according to the results of a phase 2b trial presented at the 2022 American Academy of Neurology’s Annual Meeting (AAN 2022).

Exercise contributes to an abnormal risk in pulmonary capillary wedge pressure (PCWP), but is not affected by metoprolol, in patients with obstructive hypertrophic cardiomyopathy (HCM), results of a study have shown.

Treatment with ofatumumab in the long term (approximately 3.5 years) among patients with relapsing multiple sclerosis (MS) is well-tolerated, with no new safety risks found, according to the results of ALITHIOS, presented at the 2022 Annual Meeting of the American Academy of Neurology.

The use of a combined biofeedback-virtual reality (VR) device as an add-on to standard medical care leads to a significant reduction in the need for acute medication in patients with chronic migraine, according to a study reported at the recently concluded 2022 Annual Meeting of the American Academy of Neurology (AAN 2022).

Treatment with the combination of ramucirumab and paclitaxel in the second-line setting appears to yield higher responses among patients with HER2-positive gastric or gastro-oesophageal junction adenocarcinoma than among those with HER2-negative disease, according to a subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).

The mRNA-1237 vaccine against the coronavirus disease 2019 (COVID-19) retains good immunogenicity in patients with mild antibody deficiencies and phagocyte defects, reports a recent study.

An international study led by researchers from the Chinese University of Hong Kong (CUHK) has shown a higher-than-expected incidence of adult-onset type 1 diabetes (T1D) worldwide, indicating a need for accurate diagnosis of these patients to facilitate appropriate treatment including early insulin therapy.

The primary causes of death in patients with acute myocardial infarction complicated by cardiogenic shock (AMICS) are heart failure, neurologic injury, and multiorgan failure (MOF), reports a recent study. Deaths from cardiac causes often occur within 13 hours of the first medical contact.